Both colestilan and sevelamer produced significant reductions from baseline in serum phosphorus levels ( P < 0.001 ) , maintained for 1 year , and the proportion of patients achieving target levels of 1.78 mmol/L ( 5.5 mg/dL ) or 1.95 mmol/L ( 6.0 mg/dL ) at study end were similar ( 65.3 and 73.3 % , respectively , for colestilan , and 66.9 and 77.4 % , respectively , for sevelamer ) .